What is Giiant Pharma?
Giiant Pharma is a biotechnology firm specializing in the development of gut-restricted, small molecule therapeutics designed to treat inflammatory bowel diseases (IBD). The company's proprietary technology focuses on precision delivery, utilizing the gut microbiota to bioactivate and release drugs specifically within the lower gastrointestinal tract. This approach aims to limit systemic exposure while maximizing local therapeutic action, thereby enhancing patient care and drug tolerability. Giiant Pharma is positioned to lead in precision delivery technologies, offering safer, patient-tailored treatments for gastrointestinal conditions.
How much funding has Giiant Pharma raised?
Giiant Pharma has raised a total of $12.3M across 2 funding rounds:
Angel/Seed
$11M
Angel/Seed
$1.3M
Angel/Seed (2021): $11M with participation from AmorChem, Anges Québec, Fonds de Solidarité FTQ, Genesys Capital, Theodorus Investment Funds, and Amplitude Ventures
Angel/Seed (2021): $1.3M led by Amplitude Ventures and Genesys Capital
Key Investors in Giiant Pharma
Amplitude Ventures
Amplitude Ventures is a venture capital firm that deploys a growth model to build Canadian companies with world-class management teams and scale them to breakout potential. They focus on investing in leading Canadian precision medicine companies.
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm focused on early-stage life sciences and healthcare companies, investing in biotechnology and medical innovation across North America.
AmorChem
AmorChem is a leading early-stage venture fund focused on creating the next generation of biotech companies from academic research, financing over 30 research programs and establishing several biotech companies with innovative therapeutic approaches.
What's next for Giiant Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Giiant Pharma is in a scaling phase, likely focusing on advancing its therapeutic pipeline through clinical trials and expanding its operational capacity. This capital infusion will be critical for further research and development, regulatory submissions, and potential commercialization efforts. The company's focus on precision delivery in the IBD space positions it to address unmet medical needs, attracting further investment and partnerships as it progresses.
See full Giiant Pharma company page
